Olio Labs is a biotech company developing combinatorial therapeutics for hard-to-treat diseases, targeting multiple proteins to identify synergistic

Olio Labs is a biotechnology company developing therapeutics using a combinatorial approach. Details about specific products and services require direct inquiry.
Olio Labs was founded by David Tingley, PhD (Co-Founder & CEO) and Tom Roseberry, PhD (Co-Founder & CTO). Calder Cui is also part of the team as a Software Engineer.
Olio Labs focuses on a combinatorial therapeutics approach, designed to:
The approach handles complex biological data and accounts for the broader context of protein interactions, which may enable novel treatment options and fewer side effects.
The core technology is aimed at scientists, doctors, and other professionals working in therapeutics and biological research. Some listings associate Olio Labs with creative and marketing roles such as designers and strategists, but this appears inconsistent with the company’s stated focus on biological data and therapeutics.
Visit oliolabs.co to learn more about Olio Labs’ work or explore potential collaboration with the team.
Related
Discover more tools in similar categories
Weekly picks of the best AI tools we've researched and added — no spam, unsubscribe anytime.
Join 25,000+ AI enthusiasts. No spam, unsubscribe anytime.